← 返回

纳米制剂 TLR 7/8 激动剂和 PI3k delta 抑制剂对肿瘤微环境的免疫调节增强了放疗的治疗效果

英文原题:Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy.

查看英文原题

Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy.

PubMed 2024/03/13(内容时间) bioRxiv

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

免疫抑制细胞浸润到乳腺肿瘤微环境(TME)与效应T细胞(Teff)反应受抑、肿瘤生长加速及不良临床结局相关。我们课题组及其他研究团队此前的研究发现,免疫抑制性髓源性抑制细胞(MDSC)和调节性T细胞(Treg)的浸润是原位三阴性乳腺癌(TNBC)肿瘤模型中免疫功能障碍的关键因素,限制了过继性细胞治疗的疗效。

然而,目前缺乏在TME中特异性靶向这些细胞的方法。为克服这一障碍,采用聚合物胶束纳米颗粒(PMNPs)共递送激活Toll样受体7和8(TLR7/8)并抑制PI3K delta的小分子药物。TLR7/8激动剂和PI3K抑制剂对TME的免疫调节改变了巨噬细胞极化,减少了MDSC积聚,并选择性降低了TME中的组织驻留Treg,同时增强了T细胞和B细胞适应性免疫应答。与单独RT相比,PMNPs显著增强了局部放射治疗(RT)在荷原位TNBC肿瘤小鼠中的抗肿瘤活性。

综上所述,这些数据表明RT联合纳米制剂免疫刺激剂重塑了TME,并具有未来转化用于TNBC患者联合RT治疗的良好潜力。

展开英文摘要原文

Infiltration of immunosuppressive cells into the breast tumor microenvironment (TME) is associated with suppressed effector T cell (Teff) responses, accelerated tumor growth, and poor clinical outcomes. Previous studies from our group and others identified infiltration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) as critical contributors to immune dysfunction in the orthotopic triple-negative breast cancer (TNBC) tumor model limiting the efficacy of adoptive cellular therapy.

However, approaches to target these cells specifically in the TME are currently lacking. To overcome this barrier, polymeric micelles nanoparticles (PMNPs) were used for co-delivery of small molecule drugs activating Toll-like receptors 7 and 8 (TLR7/8) and inhibiting PI3K delta. The immunomodulation of the TME by TLR7/8 agonist and PI3K inhibitor altered macrophage polarization, reduced MDSC accumulation and selectively decreased tissue-resident Tregs in the TME, while enhancing the T and B cell adaptive immune response.

PMNPs significantly enhanced the anti-tumor activity of local radiation therapy (RT) in mice bearing orthotopic TNBC tumors compared to RT alone. Taken together, these data demonstrate that RT combined with a nanoformulated immunostimulant restructured the TME and has promising potential for future translation combined with RT for patients with TNBC.

论文信息

作者
Yazdimamaghani M、Kolupaev OV、Lim C、Hwang D、Laurie SJ、Perou CM、Kabanov AV、Serody JS
文献类型
预印本
期刊
bioRxiv : the preprint server for biology2024 Mar 13
原文标识
PubMed 38559220 · DOI 10.1101/2024.03.09.584084